Filtered By:
Nutrition: Omega 3

This page shows you your search results in order of date. This is page number 10.

Order by Relevance | Date

Total 227 results found since Jan 2013.

The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Authors: Trivedi K, Le V, Nelson JR Abstract The high-purity eicosapentaenoic acid (EPA) prescription fish oil-derived omega-3 fatty acid (omega-3), icosapent ethyl (IPE), was recently approved by the United States Food and Drug Administration (FDA) for cardiovascular disease (CVD) prevention in high-risk patients. This approval is based on the 25% CVD event risk reduction observed with IPE in the pre-specified primary composite endpoint (cardiovascular [CV] death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina) in the landmark Reduction of Cardio...
Source: Postgraduate Medicine - August 13, 2020 Category: Internal Medicine Tags: Postgrad Med Source Type: research

Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis
AbstractPurpose of ReviewOmega-3 fatty acid (O3FA) supplementation has shown conflicting evidence regarding its benefit in cardiovascular events. We performed a pairwise and network meta-analysis to elucidate the benefit of different doses of O3FA supplementation in cardiovascular prevention.Recent FindingsFourteen studies were identified providing data on 125,763 patients. A prespecified cut-off value of< 1 g per day was set for low-dose (LD) O3FA and>  1 g per day for high-dose (HD) O3FA. The efficacy outcomes of interest were total death, cardiac death, sudden cardiac death, myocardial infarction, stroke, co...
Source: Current Atherosclerosis Reports - July 15, 2020 Category: Cardiology Source Type: research

Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
Purpose of review To discuss the current evidence regarding the relationship between omega-3 fatty acid intake and atherosclerotic cardiovascular disease (ASCVD) risk. Recent findings Combined results from randomized controlled trials using low-dosage (≤1.8 g/day of ethyl esters) eicosapentaenoic acid (EPA) or EPA + docosahexaenoic acid (DHA) suggest a small benefit for reducing coronary heart disease risk. The Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) that administered 4 g/day icosapent ethyl (IPE) to individuals on statin at high or very high ASCVD risk with elevated triglyceri...
Source: Current Opinion in Cardiology - June 6, 2020 Category: Cardiology Tags: LIPIDS AND EMERGING RISK FACTORS: Edited by Dimitri P. Mikhailidis and Anthony S. Wierzbicki Source Type: research

Icosapent Ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Authors: Bazarbashi N, Miller M Abstract INTRODUCTION: Icosapent Ethyl (IPE) is a highly purified (>96%) form of eicosapentanoic acid, a marine-derived omega-3 fatty acid known to reduce serum triglyceride levels. Experimental and human studies also support anti-atherosclerotic properties of IPE including antioxidant, anti-inflammatory, endothelial and plaque stabilizing effects. In the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT)l),the addition of 4 grams IPE daily resulted in a 25% reduction in cardiovascular events beyond statins and other standard of care therapies. ...
Source: Expert Review of Cardiovascular Therapy - April 2, 2020 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Efficacy of different doses of omega-3 fatty acids on cardiovascular outcomes: rationale and design of a network meta-analysis.
CONCLUSIONS: The present network meta-analysis results will aid physicians in the decision to prescribe O3FA in patients with or at risk of cardiovascular events. In particular, it will be able to solve controversies emerged from previous randomized clinical trials and meta-analyses regarding the benefit of different doses of O3FA supplementation in the cardiovascular prevention. PMID: 32107906 [PubMed - in process]
Source: Minerva Cardioangiologica - March 1, 2020 Category: Cardiology Tags: Minerva Cardioangiol Source Type: research

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
CONCLUSIONS: This is the most extensive systematic assessment of effects of omega-3 fats on cardiovascular health to date. Moderate- and low-certainty evidence suggests that increasing LCn3 slightly reduces risk of coronary heart disease mortality and events, and reduces serum triglycerides (evidence mainly from supplement trials). Increasing ALA slightly reduces risk of cardiovascular events and arrhythmia. PMID: 32114706 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - February 28, 2020 Category: General Medicine Authors: Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KH, Summerbell CD, Worthington HV, Song F, Hooper L Tags: Cochrane Database Syst Rev Source Type: research

Omega-3 fats do not protect against cancer
(University of East Anglia) Omega-3 fats do not protect against cancer -- according to new University of East Anglia research. Increased consumption of omega-3 fats is widely promoted globally because of a common belief that it will protect against, or even reverse, diseases such as cancer, heart attacks and stroke. But two systematic reviews find that omega-3 supplements may slightly reduce coronary heart disease mortality and events, but slightly increase risk of prostate cancer. Both beneficial and harmful effects are small.
Source: EurekAlert! - Cancer - February 28, 2020 Category: Cancer & Oncology Source Type: news

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
In this interview with Dr. Lee Hooper we find out more about this new Cochrane review -Omega-3 fatty acids for the primary and secondary prevention of cardiovascular diseaseTell us about this Cochrane ReviewThere is a great deal of public belief in the cardiovascular benefits of omega-3 fats.   Intakes of long-chain omega-3 fats in the US are higher from dietary supplements than foods.  But public health advice differs across countries. The National Institute for Health and Clinical Excellence in the UK encourages people to eat oily fish intake (the major source of long-chain omega-3 f ats) but discourages supplementatio...
Source: Cochrane News and Events - February 5, 2020 Category: Information Technology Authors: Katie Abbotts Source Type: news

Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review
ConclusionConsumers and health care providers need to recognize critical differences between Rx and OM-3 dietary supplements to ensure appropriate use of each OM-3 product.
Source: Advances in Therapy - January 8, 2020 Category: Drugs & Pharmacology Source Type: research

Mfsd2a Attenuates Blood-Brain Barrier Disruption After Sub-arachnoid Hemorrhage by Inhibiting Caveolae-Mediated Transcellular Transport in Rats
In this study, a prechiasmatic cistern single-injection model was used to produce experimental SAH in Sprague-Dawley rats. Specific small-interfering RNA and plasmids were used to downregulate and upregulate the expression of Mfsd2a prior to assessments in our SAH model. Omega-3 fatty acid deficiency diet was used to reduce DHA in rat brain. The expression level of Mfsd2a decreased significantly after SAH and reached its lowest level at 72  h post-SAH, which then gradually recovered. At 72 h after SAH, BBB function was disrupted; upregulation of Mfsd2a reversed this damage, whereas downregulation of Mfsd2a exacerbated th...
Source: Translational Stroke Research - January 5, 2020 Category: Neurology Source Type: research

Vitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease Current Evidence.
Abstract Whether marine omega-3 fatty acid (n-3 FA) or vitamin D supplementation can prevent cardiovascular disease (CVD) in general populations at usual risk for this outcome is unknown. A major goal of VITAL (Vitamin D and Omega-3 Trial) was to fill this knowledge gap. In this article, we review the results of VITAL, discuss relevant mechanistic studies regarding n-3 FAs, vitamin D, and vascular disease, and summarize recent meta-analyses of the randomized trial evidence on these agents. VITAL was a nationwide, randomized, placebo-controlled, 2×2 factorial trial of marine n-3 FAs (1 g/d) and vitamin D3 (2000 IU...
Source: Circulation Research - January 2, 2020 Category: Cardiology Authors: Manson JE, Bassuk SS, Cook NR, Lee IM, Mora S, Albert CM, Buring JE, VITAL Research Group Tags: Circ Res Source Type: research

Cardiometabolic disease costs associated with suboptimal diet in the United States: A cost analysis based on a microsimulation model
ConclusionsSuboptimal diet of 10 dietary factors accounts for 18.2% of all ischemic heart disease, stroke, and type 2 diabetes costs in the US, highlighting that timely implementation of diet policies could address these health and economic burdens.
Source: PLoS Medicine - December 16, 2019 Category: Internal Medicine Authors: Thiago Veiga Jardim Source Type: research

Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
ular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology Abstract Hypertriglyceridemia (triglycerides 200-499 mg/dL) is relatively common in the United States, whereas more severe triglyceride elevations (very high triglycerides, ≥500 mg/dL) are far less frequently observed. Both are becoming increasingly prevalent in the United States and elsewhere, likely driven in large part by growing rates of obesity and diabetes mellitus. In a 2002 American Heart Association scientific stat...
Source: Circulation - August 18, 2019 Category: Cardiology Authors: Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, Jacobson TA, Engler MB, Miller M, Robinson JG, Blum CB, Rodriguez-Leyva D, de Ferranti SD, Welty FK, American Heart Association Council on Arteriosclerosis, Thrombosis and Vas Tags: Circulation Source Type: research

AI may help detect atrial fibrillation from a normal rhythm ECG
Preliminary data indicate that a 10 second non-invasive test can identify US patients with intermittent abnormal heart rhythm Related items fromOnMedica ‘Silent’ heart attacks may affect one in 16 people Hypertension raises risk of mitral regurgitation Coronary heart disease remains UK ’s biggest killer Heart disease and stroke deaths plummet in Scotland Omega 3 from seafood linked to healthier ageing
Source: OnMedica Latest News - August 1, 2019 Category: UK Health Source Type: news

Survey of the Erythrocyte EPA+DHA Levels in the Heart Attack/Stroke Belt
ConclusionsIndividuals in the CVD “belt” had relatively low O3I levels. Since in other settings, a low O3I is associated with increased risk for CVD, this may be one factor contributing to the higher risk for CVD in this region of the US.
Source: Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) - July 14, 2019 Category: Lipidology Source Type: research